Research programme: anticancer monoclonal antibodies - Recepta biopharma

Drug Profile

Research programme: anticancer monoclonal antibodies - Recepta biopharma

Alternative Names: Anti-LeB antibody; mAb 58-1066; mAb A34; mAb MX35; Monoclonal antibody 58-1066 - Anti-LeB; Monoclonal antibody A34 (209-342); Monoclonal antibody MX35; RebmAb-200; RebmAb-500

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Class Monoclonal antibodies
  • Mechanism of Action Differentiation antigen inhibitors; Lewis blood group system antagonists; Type-IIb sodium-phosphate cotransporter protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Ovarian cancer

Most Recent Events

  • 20 Oct 2015 Preclinical development is ongoing in Brazil
  • 17 Mar 2008 Preclinical trials in Cancer in Brazil (Parenteral)
  • 17 Mar 2008 Preclinical trials in Ovarian cancer in Brazil (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top